[144] Progyny, Inc. SEC Filing

Rhea-AI Filing Summary

Progyny, Inc. (PGNY) filed a Form 144 reporting a proposed sale of 2,398 common shares for an aggregate market value of $55,058.08. The shares are to be sold through Fidelity Brokerage Services on the NASDAQ with an approximate sale date of 08/28/2025. The filing shows 85,982,409 shares outstanding for the class listed.

The securities were acquired on 08/28/2025 through restricted stock vesting and the consideration is listed as compensation. The filer reports no securities sold in the past three months and includes the standard representation that the selling person does not possess undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Insignificant insider sale in absolute terms; 2,398 shares ($55k) is immaterial versus the company's outstanding shares.

The filing discloses a proposed sale of 2,398 common shares acquired via restricted stock vesting and designated as compensation. Given the aggregate value of $55,058.08 and 85,982,409 shares outstanding for this class, this transaction is small relative to company capitalization and unlikely to affect market valuation or signal material insider conviction change. The absence of other sales in the past three months and the routine nature of restricted stock vesting support a neutral interpretation.

Corporate Governance Expert

TL;DR: Routine disclosure of an insider sale tied to compensation vesting; governance processes appear followed.

The Form 144 reports sale logistics (broker, exchange, date) and includes the standard certification about material nonpublic information. The securities were acquired through restricted stock vesting and sold as compensation, which is a common post-vesting disclosure. There is no indication in the filing of policy breaches, unusual timing, or aggregated recent insider disposals.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	2398	55058.08	85982409	08/28/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/28/2025	Restricted Stock Vesting	Issuer			2398	08/28/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Progyny's (PGNY) Form 144 report say?

The Form 144 reports a proposed sale of 2,398 common shares with an aggregate market value of $55,058.08, to be sold via Fidelity on 08/28/2025 on the NASDAQ.

How were the shares being sold acquired according to the PGNY filing?

The securities were acquired on 08/28/2025 through restricted stock vesting and the payment/consideration is listed as compensation.

Does the Form 144 show any other sales by the filer in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

Which broker and exchange are named in the PGNY Form 144?

The broker listed is Fidelity Brokerage Services LLC (900 Salem Street, Smithfield, RI) and the exchange is NASDAQ.

Does the filer assert possession of any undisclosed material information in the Form 144?

By signing, the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.